Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.3
(-1.14%)
SEK 1.3
(-1.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.35 Million SEK | -82.97% |
| 2022 | 13.85 Million SEK | 153.96% |
| 2021 | 5.45 Million SEK | 1000.0% |
| 2020 | 496 Thousand SEK | -89.53% |
| 2019 | 4.73 Million SEK | -79.45% |
| 2018 | 23.04 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.68 Million SEK | 87.41% |
| 2024 Q1 | 1.43 Million SEK | -39.38% |
| 2023 Q2 | 18.92 Million SEK | 18.46% |
| 2023 Q1 | 15.97 Million SEK | 15.31% |
| 2023 FY | 2.35 Million SEK | -82.97% |
| 2023 Q3 | 21.69 Million SEK | 14.65% |
| 2023 Q4 | 2.35 Million SEK | -89.13% |
| 2022 Q3 | 12.6 Million SEK | 1033.18% |
| 2022 FY | 13.85 Million SEK | 153.96% |
| 2022 Q4 | 13.85 Million SEK | 9.96% |
| 2022 Q2 | 1.11 Million SEK | 41.66% |
| 2022 Q1 | 785 Thousand SEK | -85.61% |
| 2021 FY | 5.45 Million SEK | 1000.0% |
| 2021 Q4 | 5.45 Million SEK | 276.28% |
| 2021 Q3 | 1.45 Million SEK | 13.02% |
| 2021 Q2 | 1.28 Million SEK | 39.31% |
| 2021 Q1 | 921 Thousand SEK | 85.69% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | 496 Thousand SEK | 0.0% |
| 2020 FY | 496 Thousand SEK | -89.53% |
| 2019 FY | 4.73 Million SEK | -79.45% |
| 2018 FY | 23.04 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | 82.396% |
| Biovica International AB (publ) | 34.76 Million SEK | 93.215% |
| Cantargia AB (publ) | 54.97 Million SEK | 95.709% |
| CombiGene AB (publ) | 4.15 Million SEK | 43.239% |
| Cyxone AB (publ) | 4.69 Million SEK | 49.744% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 67.507% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 82.871% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 82.3% |
| Fluicell AB (publ) | 8.91 Million SEK | 73.539% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 94.892% |
| Mendus AB (publ) | 51.22 Million SEK | 95.395% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 87.69% |
| I-Tech AB | 16.2 Million SEK | 85.443% |
| Intervacc AB (publ) | 21.68 Million SEK | 89.119% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 54.265% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 98.097% |
| OncoZenge AB (publ) | 1.69 Million SEK | -38.846% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 93.183% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.511% |
| Lipum AB (publ) | 7.53 Million SEK | 68.705% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 97.787% |
| Ziccum AB (publ) | 6.38 Million SEK | 63.071% |
| BioArctic AB (publ) | 139.5 Million SEK | 98.309% |
| Genovis AB (publ.) | 98.04 Million SEK | 97.594% |
| Camurus AB (publ) | 414.81 Million SEK | 99.431% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 96.155% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 85.363% |
| Aptahem AB (publ) | 8.99 Million SEK | 73.783% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 94.226% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 96.717% |
| Kancera AB (publ) | 17.97 Million SEK | 86.878% |
| Saniona AB (publ) | 86.08 Million SEK | 97.26% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 79.782% |
| AcouSort AB (publ) | 10.37 Million SEK | 77.269% |
| Xintela AB (publ) | 14.01 Million SEK | 83.168% |
| Abliva AB (publ) | 16.78 Million SEK | 85.942% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 79.609% |
| Amniotics AB (publ) | 10.54 Million SEK | 77.633% |
| 2cureX AB (publ) | 2.93 Million SEK | 19.625% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 46.701% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.849% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.801% |
| Biosergen AB | 5.08 Million SEK | 53.609% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 91.167% |
| Corline Biomedical AB | 6.78 Million SEK | 65.253% |
| NextCell Pharma AB | 13.68 Million SEK | 82.767% |
| Nanologica AB (publ) | 79.32 Million SEK | 97.026% |
| LIDDS AB (publ) | 3.75 Million SEK | 37.194% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.901% |
| BioInvent International AB (publ) | 90.45 Million SEK | 97.392% |
| SynAct Pharma AB | 51.83 Million SEK | 95.449% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 70.323% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 54.59% |
| Alzinova AB (publ) | 9.33 Million SEK | 74.719% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 81.489% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 98.701% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -31.494% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 87.245% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 38.536% |
| Simris Alg AB (publ) | 148.93 Million SEK | 98.416% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 96.683% |